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Abstract—The ﬁbrinogen beta-chain (FGB) -C148T polymorphism is linked with plasma ﬁbrinogen
concentration in the general population. We examined whether the -C148T polymorphism is
associated with pre- and early postoperative levels of ﬁbrinogen, C-reactive protein (CRP), and
interleukin-6 (IL-6) in 243 consecutive patients undergoing coronary artery bypass grafting
(CABG) surgery. Plasma inﬂammatory markers were measured prior to and 5–7 days after surgery.
The -C148T polymorphism was analyzed with the restriction fragment-length polymorphism method.
The genotype distribution was as follows: CC—142 (58%), CT—85 (35%), and TT—16 (7%). Carriers
of the -148T allele had higher preoperative plasma ﬁbrinogen (4.42±0.14 vs. 4.07±0.11 mg/L, p=0.04)
and CRP levels (7.49±1.2 vs. 4.26±1.0 mg/L, p=0.04) compared with non-carriers; 5 to 7 days
after CABG, patients carrying -148T allele had increased CRP (70.4±5.0 vs. 51.6±4.25 mg/L,
p=0.005) and IL-6 levels (22.34±2.64 vs. 15.53±2.28 pg/L, p=0.05), but not ﬁbrinogen, compared
with the remaining subjects. In-hospital nonfatal stroke occurred more frequently in -148Tallele carriers
(4% vs. 0%, p=0.02). No genotype-associated differences were found in the occurrence of postoperative
myocardial infarction and death. Presence of the -148T allele has also been associated with longer
intensive care stay and intubation time (p=0.01). Multivariate analysis identiﬁed the CT+TT genotype
as an independent predictor of pre- and postoperative CRP levels. The results indicate that the presence
of the -148T FGB allele determines higher pre- and postoperative levels of inﬂammatory markers, which
might be associated with in-hospital clinical outcomes.
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INTRODUCTION
Fibrinogen is encoded by three separate genes
located in a 50-Kb cluster on the long arm of
chromosome 4, which encode for the α, β, and γ chains
[1]. The rate limiting step in ﬁbrinogen formation is
the synthesis of the β-polypeptide chain regulated by a
β-ﬁbrinogen promoter [2]. One of the polymorphisms
identiﬁed within this region is -C148T mutation located
close to an interleukin-6-response element affecting
ﬁbrinogen gene expression, mainly in response to the
acute-phase reaction [3]. This polymorphism is in
complete allelic association with -G455A in white
population [4]. Several studies have shown that a -C148T
polymorphism is associated with increased plasma
ﬁbrinogen levels in men and women in the general
population [5–7]. Fibrinogen conversion to ﬁbrin is
the ﬁnal step in the blood coagulation. Moreover,
ﬁbrinogen acts as a bridging molecule for many types
of cell–cell adhesion events critical in atherogenesis
[8]. Fibrinogen synthesis is upregulated primarily by
interleukin-6 (IL-6) which controls the hepatic production
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of C-reactive protein (CRP). The studies included
both genders, European and American cohorts, both
middle-aged and elderly patients showed that in
addition to predicting cardiovascular death and
myocardial infarction, CRP is also a robust predictor
of stroke [9].
Coronary artery bypass grafting (CABG) procedure
is a strong inﬂammatory stimulus that causes a
substantial rise in circulating CRP, ﬁbrinogen, and
IL-6 levels [10–12]. Patients having CRP value
greater or equal to 3.3 mg/l preoperatively suffered
from myocardial damage, heart failure, or stroke
during ﬁrst 30 days after CABG [13]. High-plasma
IL-6 concentrations were in turn signiﬁcantly associated
with postoperative fever [10], atrial ﬁbrillation [14],
prolonged endotracheal intubation time, and duration
of intensive care [15, 16]. Inﬂammatory response
after CABG might be modiﬁed by polymorphisms in
pro-inﬂammatory genes. Brull et al. showed that high
CRP level was signiﬁcantly and independently associated
with +C1444T CRP gene polymorphism at 72 h after
CABG surgery [11]. Similarly, the G/A transitions within
the promoter region of the TNF-α gene and the ﬁrst
intron of the TNF-β gene were associated with
elevated levels of TNF-α up to 48 h after surgery
[17]; 5 to 7 days after CABG, signiﬁcant increase of
CRP and IL-6 levels was determined by IL-6 -174G/C
polymorphism: patients carrying -174C allele had
CRP and IL-6 levels higher than those with -174GG
genotype [15].
The aim of our study was to assess whether -C148T
FGB polymorphism is associated with acute-phase




We recruited 243 consecutive white patients
with stable angina admitted to the Department of
Cardiovascular Surgery and Transplantation, Institute
of Cardiology, Jagiellonian University School of
Medicine for elective isolated CABG surgery between
January and September 2006. Inclusion criteria were as
follows: signiﬁcant stenosis in the left main coronary artery
(>50%) or major epicardial arteries (>70%) determined by
coronary angiography in patients who were not scheduled
for percutaneous coronary intervention. The exclusion
criteria were other surgical procedures on the same
day, emergency operation, signs, or symptoms of
acute infections, treatment with vitamin K antagonists,
heparins, or thienopyridines, a history of venous
thromboembolism, a previous acute coronary syndrome
within less than 3 months prior to surgery, serious
concomitant diseases such as cancer, autoimmune
disorders, end-stage renal insufﬁciency, liver injury,
presence of extensive dental disease. Patients with
preoperative CRP >10 mg/l were excluded from the
ﬁnal analysis because there was a high probability of
chronic inﬂammatory state of unknown origin.
In case of an elevated fasting glucose a conﬁrmatory
test (a 75-g oral glucose tolerance test) was made to screen
for diabetes. Arterial hypertension was diagnosed if
diastolic blood pressure exceeded 90 mmHg and/or
systolic pressure was >140 mmHg at least two times or
the use of antihypertensive drugs at a positive history of
this disease. Ischemic stroke was diagnosed according to
the WHO criteria [18]. The diagnosis of perioperative
myocardial infarction (PMI) was based on the criteria
published in 2004 [19]. The University Ethical Committee
approved the study, and participants provided informed
consent.
Laboratory Investigations
Blood samples were drawn from an anticubital vein
with minimal stasis after an overnight fast. Lipid
proﬁles, glucose, and creatinine were assayed by routine
laboratory techniques. Fibrinogen was determined using
the Clauss method [20]. High-sensitivity CRP was
measured by an immuno-turbidimetric assay (Dade
Behring, Marburg, Germany). A commercially available
immunoenzymatic assay was used to determine serum
IL-6 levels (R&D System Inc., Minneapolis, USA). The
minimal detectable IL-6 concentration was 0.03 pg/ml.
All measurements were performed by technicians
blinded to the origin of the samples. Intra- and inter-assay
coefﬁcients of variation were <7%.
DNA Extraction and Genotyping
DNA was extracted from whole blood or a buffy
coat according to the manufacturer’s protocol using the
GenElute™ Blood Genomic DNA Kit (Sigma–Aldrich)
and stored at −20°C until analysis. The polymorphism of
the ﬁbrinogen beta-chain gene -C148T was genotyped
by PCR and restriction fragment-length polymorphism
method using primer pairs 5′ CCTAACTTCCCAT
CATTTTGTCCAATTAA 3′/5 ′ TGTCGTTGACA
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CCTTGGGACTTAAC TAG-3′ and Hind III digestion
(recognition sequence—AAGCTT) resulted in fragments
of 97 and 265 bp for the C allele (-148C) or 362 bp for the
T allele (-148T) [21].
Statistical Analysis
Data are given as means ±SD unless otherwise
stated. The Kolmogorov–Smirnov test was used to
assess conformity with a normal distribution. Allele
frequencies were estimated by gene counting. The χ2
test was used to compare the observed numbers of
each genotype with those expected for a population in
Hardy–Weinberg equilibrium. The variables were
compared with Student’s t test and analysis of
variance. Correlations were assessed by the
Spearman test. To identify independent factors of
CRP levels, a stepwise multivariate linear regression
analysis was used in which a p value less than 0.05 in
a simple regression analysis was served as the
criterion for entry into the model. Variables showing
established cardiovascular risk factors were also
included. The logistic regression analysis was
employed to estimate the odds ratio and 95%
coefﬁcient intervals (CIs) as a relative risk of PMI
with the prevalence of a mutant allele and the levels
of acute phase proteins. A value of p<0.05 was
considered statistically signiﬁcant. Analysis was




Among the 243 patients who underwent CABG
surgery, 185 (76%) were male. A mean age of the
patients was 64.6±8.2 (range from 42 to 82) years. A
mean body mass index (BMI) was 28±4.0 kg/m2. Two
hundred twenty-ﬁve patients (92%) were treated with
statins, 218 (90%) with beta-blockers, 211 (87%) with
angiotensin-converting enzyme inhibitors, 23 (9%) with
acetylsalicylic acid. Sixty-seven subjects (27.6%) were
current smokers. Arterial hypertension was diagnosed in
207 (85%) patients, previous myocardial infarction in
197 (81%) patients, diabetes in 70 (29%), chronic
Table 1. Baseline Demographic and Clinical Characteristic of Patients with Regard to -C148T FGB Polymorphism
Demographic and clinical data CC (n=142) CT+TT (n=101) p Value
Age, years 64.34±0.69 65.27±0.82 0.39
Male gender, n (%) 109 (77) 76 (75) 0.68
BMI, kg/m2 27.85±0.34 28.17±0.4 0.55
Current smokers, n (%) 38 (27) 29 (29) 0.78
Hypertension, n (%) 122 (86) 85 (84) 0.68
Diabetes, n (%) 37 (26) 33 (33) 0.3
COPD, n (%) 10 (7) 3 (3) 0.17
Previous MI, n (%) 114 (80) 83 (82) 0.71
Medications
ASA, n (%) 21 (15) 2 (2) 0.25
Statins, n (%) 129 (91) 96 (95) 0.28
β-blockers, n (%) 131 (92) 87 (86) 0.12
ACE inhibitors, n (%) 124 (87) 87 (86) 0.89
Laboratory parameters
Glucose, mmol/L 5.51±0.11 6.12±0.65 0.07
Creatinine, μmol/L (n=144) 86.56±2.36 77.60±2.88 0.02
TC, mmol/L 4.69±0.09 4.59±0.11 0.45
HDL-C, mmol/L 1.24±0.02 1.2±0.03 0.35
LDL-C, mmol/L 2.96±0.08 2.90±0.09 0.46
TG, mmol/L 1.61±0.09 1.85±0.1 0.07
CRP, mg/L 4.26±1.01 7.49±1.2 0.04
Fbg, g/L 4.07±0.11 4.42±0.14 0.04
Values are given as mean±SD or number (percentage)
ACE angiotensin-converting enzyme, ASA acetylsalicylic acid, BMI body mass index, MI myocardial infarction, CRP C-reactive protein, COPD
chronic obstructive pulmonary disease, Fbg ﬁbrinogen, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC
total cholesterol, TG triglycerides
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obstructive pulmonary disease (COPD) in 13 (5%). The
mean Euroscore was 5.2±1.55.
-C148T Polymorphism
We identiﬁed 142 subjects with -148C genotype, 85
heterozygous and 16 patients homozygous for the -148T
allele. Genotype distribution did not differ signiﬁcantly
from that predicted by the Hardy–Weinberg equilibrium
law (χ2=0.45). The T allele frequency was 24.0%, a
ﬁnding consistent with studies in other European and
Caucasian populations of the -C148T (or -G455A)
polymorphisms [21]. Both genotype groups did not
differ with regard to cardiovascular risk factors and
medications (Table 1). There were no inter-group
differences in glucose and lipid proﬁle, but ﬁbrinogen
and CRP levels were higher in T allele carriers than in
CC patients (4.42±0.14 vs. 4.07±0.11 g/L, p=0.04;
7.49±1.2 vs. 4.26±1.01 mg/L, p=0.04, respectively).
Higher serum creatinine levels were observed in CC
patients (Table 1). Creatinine concentrations did not
correlate with inﬂammatory markers and did not
predict clinical outcomes in our group.
As expected, there was a positive correlation between
baseline CRP and IL-6 concentrations (r=0.5, p<0.0001).
The basal ﬁbrinogen levels were positively correlated with
CRP (r=0.6, p<0.0001) and IL-6 (r=0.4; p<0.0001) levels.
CABG and Perioperative Clinical Outcomes
The surgery was performed by four cardiac
surgeons using a standard cardiopulmonary bypass
technique. The number of grafts per patient was 2.65±
0.70. The mean aortic cross clamp time was 40.9±14.1
(range 12–100) min. The mean duration of extracorporeal
circulation was 89.6±33.8 (range 40–270) min. Intensive
care stay was 2.8±4.2 days. There were no associations
between -C148T FGB polymorphism and any procedure-
related variables; however, intubation time and the length
of intensive care unit stay were prolonged in T allele
carriers (Table 2).
During hospital stay, there were 22 major adverse
cardiovascular events, including ﬁve cardiovascular
deaths, 13 myocardial infarctions, and four ischemic
strokes. The logistic regression analysis showed that
basal ﬁbrinogen levels in patients in the highest quartile
was associated with a 8.8-fold increased risk of
perioperative MI in CABG patients (95% CI=2.01 to
40.46, P=0.004). The frequency of adverse cardiovascular
events, cardiovascular deaths, and PMI was similar in
patients with -148T allele and those with CC genotype.
Interestingly, four nonfatal ischemic strokes were observed
among -148T allele carriers during postoperative period,
while no such episode occurred in the CC patients
(Table 3). Patients with stroke had higher CRP levels
compared to those without this complication (19.9±6.0 vs.
5.4±0.8 mg/L, p=0.005).
The Inﬂammatory Response after CABG
CRP, ﬁbrinogen, and IL-6 levels measured post-
operatively were available in only 124 patients. We
initially recruited 243 patients, but 119 subjects were
excluded from the postoperative analysis due to
incomplete clinical and laboratory data (n=19), transfer
to other wards (n=95), or patient refusal (n=5).
Five to seven days after CABG, mean CRP
increased more than 10-fold from 4.3±0.1 to 62.5±
4.2 mg/L (p<0.0001). A mean IL-6 rose 6-fold from
3.1±0.23 preoperatively to 20.05±2.4 pg/mL after
surgery (p<0.0001). The magnitude of a postoperative
Table 2. Procedure-Related Data in Relation to -C148T FGB Polymorphism
Operative details CC (n=142) CT+TT (n=101) p Value
Euroscore, per patient 2.66±0.14 2.78±0.17 0.6
Drainage, mL 744.96±35 784.12±42.96 0.5
Number of grafts, per patient 2.61±0.06 2.75±0.07 0.1
Aortic cross clamp, min 40.38±1.21 41.76±1.47 0.5
Extracorporeal circulation, min 86.4±2.69 91.75±3.27 0.2
Intubation time, days 1.26±0.24 2.2±0.29 0.01
Intensive care stay, days 2.14±0.35 3.63±0.41 0.007
Table 3. Major Adverse Cardiovascular Events During Perioperative
Period in Relation to -C148T FGB Polymorphism
Cardiovascular events CC n (%) CT+TT n (%) p Value
Death 1 (0.7) 4 (4) 0.2
Non-fatal MI 8 (6) 5 (5) 0.8
Non-fatal stroke 0 (0) 4 (4) 0.02
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increase in CRP levels was associated with post-
operative ﬁbrinogen (r=0.4, p<0.0005) and IL-6
levels (r=0.53, p<0.0001), intubation time (r=0.24,
p=0.01), and duration of intensive care (r=0.25, p=0.01).
The IL-6 rise following surgery was positively
correlated with postoperative ﬁbrinogen (r=0.3, p=0.02)
and CRP levels (r=0.5, p<0.0001).
Five to seven days after surgery carriers of the -148T
allele had 36% higher CRP and 44% higher IL-6
levels than those having -148CC genotype (70.4±5.0 vs.
51.6±4.25 mg/L, p=0.005 and 22.34±2.64 vs. 15.53±
2.28 pg/ml, p=0.05, respectively; Fig. 1). Multivariate
regression analysis including sex, age, BMI, smoking,
COPD, hypertension, diabetes, and CT+TT genotype
identiﬁed COPD and CT+TT genotype as the independent
predictors of basal CRP levels (R2=0.1, p=0.02) in
coronary artery disease (CAD) patients (Table 5); 5 to
7 days following surgery CT+TT genotype was the
only independent predictor of postoperative CRP levels
(R2=0.1, p=0.03, Table 4).
DISCUSSION
This study shows that beta-ﬁbrinogen gene -C148T
polymorphism modulates concentrations of the acute
phase proteins in patients with advanced CAD. Baseline
plasma ﬁbrinogen and CRP levels as well as CRP and
IL-6 levels measured 5–7 days following CABG were
signiﬁcantly higher in -148T allele carriers. It should be
highlighted that the inﬂuence of -C148T polymorphism
on inﬂammatory markers is potent enough to be
detected in the early postoperative period in patients
undergoing CABG. Postoperative ﬁbrinogen appears
to be subjected to other strong modulators and the
effect of -148T allele on ﬁbrinogen is abolished after
surgery.
The acute-phase proteins may be involved in the
occurrence of perioperatve adverse events in CABG
patients. Indeed, patients in the highest quartile of
ﬁbrinogen levels had increased risk of PMI (odds ratio
8.8). Perioperative MI worsens prognosis in patients
after CABG surgery, both during short- and long-term
follow-up [22, 23]. Patients with PMI were more
likely to have a cardiac event within 30 months after
operation [24]. Furthermore, 3-year survival averaged
85% of patients with PMI compared with 95% of
patients without such a cardiac event at operation
[25]. Moreover, we showed that CRP levels might be
also affected by -C148T FBG polymorphism. There is
evidence that preoperative elevated CRP levels are
associated with a signiﬁcantly increased risk of post-
operative death [26], heart failure [13], low cardiac
output syndrome [27], recurrent ischemia [28], or stroke
Fig. 1. Baseline (a, c) and postoperative (b, d) CRP and IL-6 levels
determined in -148CC and -148T carriers. Values are given as mean±
standard deviation.
Table 4. Multiple Regression Analysis for the Risk Factors and Basal and Postoperative CRP Levels
CRP R2=0.11, p=0.02 CRP after CABG R2=0.10, p=0.03
Beta SE p Beta SE p
Sex 0.09 0.07 0.17 −0.10 0.08 0.19
Age 0.12 0.07 0.09 0.001 0.08 0.99
BMI −0.03 0.07 0.70 0.12 0.08 0.15
Smoking −0.02 0.07 0.80 0.08 0.08 0.30
Hypertension 0.04 0.07 0.58 0.09 0.08 0.23
Diabetes −0.01 0.07 0.16 −0.05 0.08 0.57
COPD 0.17 0.07 0.01 0.21 0.07 0.30
-C148T FGB polymorphism 0.15 0.07 0.03 0.15 0.07 0.05
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[13] during follow-up. The inﬂammatory pathways may
be important mechanistic factors in either initiating or
otherwise modulating stroke after cardiac surgery [9, 29].
We extended these ﬁndings by showing that the presence
of the T allele might affect in-hospital adverse outcomes
following CABG. In the current study, the incidence of
perioperative nonfatal ischemic stroke was observed in
four of -148T allele carriers who had signiﬁcantly
higher CRP levels than patients without stroke. It
might be speculated that the beta-ﬁbrinogen gene -C148T
polymorphism contributes to the etiology of perioperative
stroke by modulating the ﬁbrinogen and CRP expression.
Perioperative strokes result in a prolonged hospital stay,
increased rates of disability, and discharge to long-term
care facilities [30].
We found that CT+TT genotype is an independent
predictor of high postoperative CRP levels in CABG
patients. Inﬂammatory gene polymorphism associatedwith
variation in concentrations of inﬂammatory markers has
additional impact on severity of inﬂammation after surgery.
This enhanced inﬂammatory reaction might be connected
with different cardiovascular events developed in the
postoperative period [31, 32]. In our study, the prolonged
endotracheal intubation time and the duration of intensive
care were associated with the Tallele presence linked with
the considerable increase of in-hospital stay. Carrying
of the -148T allele has also been associated with
increased postoperative IL-6 levels in CABG patients.
It is known that IL-6 exert its inﬂammatory effects
by upregulating ﬁbrinogen expression and the -C148T
polymorphism is a major regulator of this process [33].
Moreover, the -C148T polymorphism affects plasma
ﬁbrinogen levels only in subgroups with higher IL-6 and
CRP levels such as healthy smokers [34]. It seems that
the -C148T polymorphism may affect not only ﬁbrinogen
gene expression but also other pro-inﬂammatory proteins
like CRP at transcriptional level. Further studies will,
therefore, be necessary to clarify this association.
This study has limitations. First, patients were not
followed after hospital discharge. A 1-year or longer
follow-up might provide new insights into the genetic
background of postoperative inﬂammatory response and
its association with long-term prognosis following
CABG. Secondly, the sample size was limited, and the
number of cardiovascular events recorded following
surgery during hospital stay is rather low. Analysis of
subgroups could be just underpowered to show signiﬁcant
differences. Third, CRP, ﬁbrinogen, and IL-6 levels
measured 5–7 days after CABG were available not
in all patients. Therefore, we cannot exclude that
subjects with severe comorbidities were not included
in the postoperative analysis. Finally, the data cannot
be extrapolated to emergency or urgent CABG, in
which acute phase reaction is usually more potent.
In conclusion, we found that -C148T FGB poly-
morphism was an independent predictor of pre- and early
postoperative CRP levels in CABG patients. Preoperative
ﬁbrinogen levels and postoperative IL-6 levels were higher
in T allele carriers. Polymorphism in pro-inﬂammatory
genes may modulate the severity of inﬂammation and be
associatedwith clinical outcomes in the early postoperative
period in patients undergoing elective CABG.
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